Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma

F Stephen Hodi, MD1, Jason Chesney, MD2,*, Anna C Pavlick, MD3, Caroline Robert, MD4,*, Kenneth F. Grossmann, MD5, David F McDermott, MD6, Gerald P Linette, MD7, Nicolas Meyer, MD8,*, Jeffrey K Giguere, MD9, Sanjiv S Agarwala, MD10,*, Montaser Shaheen, MD11, Marc S Ernstoff, MD12,*, David R Minor, MD13, April K Salama, MD14, Matthew H Taylor, MD15, Patrick A Ott, MD1, Christine Horak, PhD16, Paul Gagnier, MD16, Joel Jiang, PhD16, Jedd D Wolchok, MD17,*, and Michael A Postow, MD17 1Dana-Farber Cancer Institute, Boston, MA, USA

[1]  M. Atkins,et al.  Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. , 2016 .

[2]  J. Wolchok,et al.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[3]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[4]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[5]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[6]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[7]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[8]  J. Wolchok,et al.  Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[11]  J. Haanen,et al.  Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[13]  A. Hauschild,et al.  The Oncologist® Academia–Pharma Intersect: Melanoma , 2022 .

[14]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.